Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Carisma Therapeutics is raising $70,352,521.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Steven Kelly played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Carisma Therapeutics

Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease. Our unique therapeutic approach uses CAR technology to endow human macrophages with the ability to recognize specific targets and triggers macrophage phagocytic and antigen-presenting functions to attack cancer.

To learn more about Carisma Therapeutics, visit http://carismatx.com/

Contact:
Steven Kelly, President and Chief Executive Officer
484-899-0326
steven.kelly@carismatx.com
https://www.linkedin.com/in/skelly5/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved